Relmada Therapeutics downgraded by Oppenheimer with a new price target

10/13/22 11:59:44 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer downgraded Relmada Therapeutics from Outperform to Perform and set a new price target of $7.00 from $64.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RLMD

Date	Price Target	Rating	Analyst
12/5/2024	$23.00 → $1.00	Outperform → Neutral	Mizuho
9/17/2024	$3.50 → $13.00	Hold → Buy	Jefferies
6/5/2024	$3.00 → $2.00	Neutral → Sell	Goldman
10/14/2022	$81.00 → $8.00	Buy → Neutral	Goldman
10/14/2022	$90.00 → $10.00	Buy → Hold	Truist
10/14/2022		Buy → Neutral	Guggenheim
10/13/2022	$64.00 → $7.00	Outperform → Perform	Oppenheimer
12/20/2021	$50.00 → $42.00	Outperform	SVB Leerink